Amendment to Collaborative Study and Research Agreement

Lixte Biotechnology Holdings, Inc. has entered into Amendment No. 2 to the GSK & LIXTE Supported Collaborative Study, originally established on September 18, 2023, and amended on April 4, 2025. This amendment, effective December 17, 2025, expands the study to include 42 patients, an increase from the original 21. GSK and Lixte will provide necessary drugs for the additional patients. Additionally, Lixte has entered into a Collaborative Research Agreement with the Anderson Cancer Center. Under this agreement, Lixte will make milestone payments totaling $1.5 million upon the initiation of a pivotal clinical trial, achievement of Breakthrough Therapy or Accelerated Approval designation, and FDA approval for LB-100 in clear cell ovarian cancer. Lixte will also pay a 3.75% royalty on net profits from LB-100 or related products. This expansion and research agreement are detailed in Exhibits 10.1 and 10.2.